Decorin is responsible for progression of non-small-cell lung cancer by promoting cell proliferation and metastasis
- 408 Downloads
Decorin, a member of the small leucine-rich proteoglycans family, exists and plays multifunctional roles in stromal and epithelial cells. Emerging evidences showed that decorin is dysregulated expression in a wide variety of human tumors and affects a broad biology process of cancer cells, including growth, metastasis, and angiogenesis. Recent studies demonstrated that decorin could affect A549 proliferation though decreasing TGF-β1, cycling D1 expression and increasing P53 and P21 expression. However, limited data are available on the effect of decorin on metastasis of non-small-cell lung cancer (NSCLC) cell lines and how decorin impacts metastasis is still unknown. In this study, we identified decorin mRNA expression through Oncomine database and verified the expression of decorin mRNA and protein in 50 patients who underwent primary surgical resection of a NSCLC in the Department of Thoracic Surgery, Jinling Hospital, Nanjing University School of Medicine, China, between September 2013 and March 2014 by quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) and Western blot. Also, the correlationship between decorin and the NSCLC patients’ clinical characteristics or survival (www.kmplot.com) was analyzed. Via ectopic expression analyses and Western blot, the roles of decorin in proliferation, metastasis, and the underline mechanism for decorin expression were further explored. We found that decorin was downregulated in NSCLC tissues compared with the adjacent normal lung tissues or normal tissues. Additionally, the expression of decorin was correlated with tumor size, lymph node metastasis, tumor stage, and prognosis. We also showed that overexpression of decorin could inhibit NSCLC cell lines proliferation and metastasis. Through Western blot analysis, we identified that E-cadherin and vascular endothelial growth factor (VEGF) are two key factors responsible for the growth arrest and metastasis inhibition induced by decorin in NSCLC. Our results indicated that decorin plays crucial roles in NSCLC against carcinogenesis and progression. Decorin might be a predictive factor and an attractive therapeutic target for NSCLC patients.
KeywordsDecorin NSCLC Proliferation Metastasis
Non-small-cell lung cancer
American Cancer Society
Small leucine-rich repeat proteoglycans
Fetal bovine serum
Vascular endothelial growth factor
This work was supported by grants from the National Natural Science Foundation of China (No. 81170064) and the Natural Science Foundation of China (No. 81302032). We apologize to all researchers whose relevant contributions were not cited due to space limitations.
Conflict of interest
- 2.Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT, et al. Non-small cell lung cancer. J Natl Compr Cancer Netw. 2010;8(7):740–801.Google Scholar
- 15.Buraschi S, Neill T, Owens RT, Iniguez LA, Purkins G, Vadigepalli R, et al. Decorin protein core affects the global gene expression profile of the tumor microenvironment in a triple-negative orthotopic breast carcinoma xenograft model. PLoS One. 2012;7(9):e45559. doi: 10.1371/journal.pone.0045559.CrossRefPubMedPubMedCentralGoogle Scholar
- 17.Hu Y, Sun H, Owens RT, Wu J, Chen YQ, Berquin IM et al. Decorin suppresses prostate tumor growth through inhibition of epidermal growth factor and androgen receptor pathways. Neoplasia (New York, NY). 2009;11(10):1042–53.Google Scholar
- 18.Yu X, Zou Y, Li Q, Mao Y, Zhu H, Huang G, et al. Decorin-mediated inhibition of cholangiocarcinoma cell growth and migration and promotion of apoptosis are associated with E-cadherin in vitro tumour biology. J Int Society Oncodevelopmental Biology and Medicine. 2014;35(4):3103–12. doi: 10.1007/s13277-013-1402-y.CrossRefGoogle Scholar
- 23.Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia (New York, NY). 2007;9(2):166–80.Google Scholar
- 27.Nash MA, Deavers MT, Freedman RS. The expression of decorin in human ovarian tumors clinical cancer research. J Am Association for Cancer Res. 2002;8(6):1754–60.Google Scholar
- 28.Smid-Koopman E, Blok LJ, Chadha-Ajwani S, Helmerhorst TJ, Brinkmann AO, Huikeshoven FJ. Gene expression profiles of human endometrial cancer samples using a cDNA-expression array technique: assessment of an analysis method. Br J Cancer. 2000;83(2):246–51. doi: 10.1054/bjoc.2000.1238.CrossRefPubMedPubMedCentralGoogle Scholar
- 29.Leygue E, Snell L, Dotzlaw H, Troup S, Hiller-Hitchcock T, Murphy LC et al. Lumican and decorin are differentially expressed in human breast carcinoma. The Journal of pathology. 2000;192(3):313–20. doi: 10.1002/1096-9896(200011)192:3 < 313::aid-path694 > 3.0.co;2-b.
- 30.Troup S, Njue C, Kliewer EV, Parisien M, Roskelley C, Chakravarti S, et al. Reduced expression of the small leucine-rich proteoglycans, lumican, and decorin is associated with poor outcome in node-negative invasive breast cancer clinical cancer research. J Am Association for Cancer Research. 2003;9(1):207–14.Google Scholar
- 41.Neill T, Painter H, Buraschi S, Owens RT, Lisanti MP, Schaefer L, et al. Decorin antagonizes the angiogenic network: concurrent inhibition of Met, hypoxia inducible factor 1alpha, vascular endothelial growth factor A, and induction of thrombospondin-1 and TIMP3. J biological chem. 2012;287(8):5492–506. doi: 10.1074/jbc.M111.283499.CrossRefGoogle Scholar